Skip to main content
Premium Trial:

Request an Annual Quote

Dawn Berry

Dawn Berry has become president of Luna DNA, a genomic and medical research database powered by the blockchain and owned by its community. Previously, she was vice president of applied genomics at Illumina, which she joined in 2005 as a market development specialist. Prior to that, she was with Genaissance Pharmaceuticals, promoting clinical genetics testing services for pharmaceutical trials. Berry holds a BS in biology from the University of Vermont and an MBA from the University of Connecticut School of Business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.